$500K
+$500K this year1 filing since 2026 · latest Equity filed
Jupiter Biomedical Research is a preclinical-stage drug development company in Palm Beach Gardens, Florida, formed to commercialize two internally developed small-molecule candidates. Its lead oncology candidate, JBR-102, is a new chemical entity advanced through IND-enabling preclinical studies for glioblastoma multiforme, an aggressive brain cancer, with additional activity reported against prostate, lung and colon cancers, melanoma and blood cancers. Its second candidate, JBR-201, is an antiviral compound focused initially on measles and herpes virus strains. The company is not a contract research organization; it owns and develops its own therapeutic pipeline.
What sets it apart
Two internally discovered new chemical entities rather than in-licensed assets, with JBR-102 reported to retain potency against tumor cells whether actively dividing or in the biosynthetic phases preceding cell division, and now being reformulated from intravenous to oral administration.
A new chemical entity advanced through preclinical, IND-enabling studies as a treatment for glioblastoma multiforme, originally formulated for intravenous delivery in late-stage GBM and being redesigned as an oral medication.
